Next Article in Journal
Piloting a Regional Collaborative in Cancer Surgery Using a “Community of Practice” Model
Previous Article in Journal
Exploring a “community of practice” methodology as a regional platform for large-scale collaboration in cancer surgery—the Ottawa approach
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

1
R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, and Department of Oncology, Queen’s University, Kingston, ON
2
Department of Pharmacy, Centre hospitalier de l’Université de Montréal, and Faculty of Pharmacy, University of Montreal, Montreal, QC
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(1), 19-26; https://doi.org/10.3747/co.21.1740
Received: 12 December 2013 / Revised: 1 January 2014 / Accepted: 15 January 2014 / Published: 1 February 2014
Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (xnsclcs). Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients. Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine. Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur. Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs. The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib.
Keywords: anaplastic lymphoma kinase inhibitors; ALK; crizotinib; adverse events; lung cancer anaplastic lymphoma kinase inhibitors; ALK; crizotinib; adverse events; lung cancer
MDPI and ACS Style

Rothenstein, J.M.; Letarte, N. Managing Treatment–Related Adverse Events Associated with Alk Inhibitors. Curr. Oncol. 2014, 21, 19-26. https://doi.org/10.3747/co.21.1740

AMA Style

Rothenstein JM, Letarte N. Managing Treatment–Related Adverse Events Associated with Alk Inhibitors. Current Oncology. 2014; 21(1):19-26. https://doi.org/10.3747/co.21.1740

Chicago/Turabian Style

Rothenstein, J.M.; Letarte, N. 2014. "Managing Treatment–Related Adverse Events Associated with Alk Inhibitors" Curr. Oncol. 21, no. 1: 19-26. https://doi.org/10.3747/co.21.1740

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop